Immunocore announced updated Phase 1/2 data for brenetafusp in heavily pretreated advanced melanoma patients, showing a 6-month overall survival rate of 87% and a disease control rate of 52%. The 160 mcg dose demonstrated better clinical outcomes and will be used in the ongoing Phase 3 PRISM-MEL-301 trial combining brenetafusp with nivolumab for first-line treatment. Brenetafusp was well tolerated both as monotherapy and combined with pembrolizumab, offering hope for patients resistant to prior PD-1 therapies. These results support further development of brenetafusp as a promising treatment for advanced melanoma.
Apple's stock surged 15% in May, driven by optimism around its future in AI, particularly the potential of 'agentic smartphones.' Bank of America raised Apple's price target to $380, highlighting this AI opportunity as a key growth driver. Meanwhile,...
Victoria Hanrahan, a senior manager at Nokia Corporation, purchased a total of 44,682 shares on May 26 and May 28, 2026. The shares were acquired on the New York Stock Exchange at an average price of $15.81 per share. This transaction signals confide...
Victoria Hanrahan, a senior executive at Nokia, acquired a total of 44,682 Nokia shares on May 26 and May 28, 2026. The shares were purchased on the New York Stock Exchange at average prices of $16.02 and $15.60 respectively, with a combined average ...
Robert Kiyosaki warns investors against following hype blindly amid Bitcoin's recent price correction near $73,700. He emphasizes that education and understanding cash flow, risk, and timing are more important than simply buying assets like Bitcoin, ...
Leo Nelissen emphasizes energy as a top investment due to global demand growth, constrained supply, and favorable valuations compared to the S&P 500. He recommends specific stocks across the energy supply chain, including LandBridge, Viper Energy, an...
